title: Oral administration of whole dihomo-γ-linolenic acid-producing Saccharomyces cerevisiae suppresses cutaneous inflammatory responses induced by croton oil application in mice.
abstract: Polyunsaturated fatty acids have been attracting considerable interest because of their many biological activities and important roles in human health and nutrition. Dihomo-γ-linolenic acid (DGLA; C20: 3n-6) is known to have an anti-inflammatory activity, but its range of effects was not well studied because of its limited natural sources. Taking advantage of genetic tractability and increasing wealth of accessible data of Saccharomyces cerevisiae, we have previously constructed a DGLA-producing yeast strain by introducing two types of desaturase and one elongase genes to convert endogenous oleic acid (C18:1n-9) to DGLA. In this study, we investigated the efficacy of oral intake of heat-killed whole DGLA-producing yeast cells in the absence of lipid purification on cutaneous inflammation. Topical application of croton oil to mouse ears induces ear swelling in parallel with the increased production of chemokines and accumulation of infiltrating cells into the skin sites. These inflammatory reactions were significantly suppressed in a dose-dependent manner by oral intake of the DGLA-producing yeast cells for only 7 days. This suppression was not observed by the intake of the γ-linolenic acid-producing (C18:3n-6, an immediate precursor of DGLA) yeast, indicating DGLA itself suppressed the inflammation. Further analysis demonstrated that DGLA exerted an anti-inflammatory effect via prostaglandin E1 formation because naproxen, a cyclooxygenase inhibitor, attenuated the suppression. Since 25-fold of purified DGLA compared with that provided as a form of yeast was not effective, oral administration of the whole DGLA-producing yeast is considered to be a simple but efficient method to suppress inflammatory responses.
authors: Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, Chiba, 274-8510, Japan, naokow@biomol.sci.toho-u.ac.jp.
authors: Naoko
authors: N
authors: Watanabe
authors: Daiki
authors: D
authors: Masubuchi
authors: Maki
authors: M
authors: Itoh
authors: Soichiro
authors: S
authors: Teradu
authors: Hisashi
authors: H
authors: Yazawa
authors: Hiroshi
authors: H
authors: Uemura
mesh_terms: D015126:8,11,14-Eicosatrienoic Acid / Q000378:metabolism*; D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000378:metabolism*; D001691:Biological Therapy / Q000379:methods*; D003436:Croton Oil / Q000633:toxicity*; D003872:Dermatitis / Q000517:prevention & control*; D004195:Disease Models, Animal; D060847:Metabolic Engineering; D051379:Mice; D019301:Oleic Acid / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000235:genetics / Q000378:metabolism*
chemical_list: D000893:Anti-Inflammatory Agents; D019301:Oleic Acid; D003436:Croton Oil; D015126:8,11,14-Eicosatrienoic Acid